Cell-Free MicroRNA Expression Profiles in Malignant Effusion Associated with Patient Survival in Non-Small Cell Lung Cancer

被引:52
作者
Wang, Tingting [1 ,2 ,3 ,4 ,5 ]
Lv, Mingming [1 ,2 ,3 ]
Shen, Sunan [1 ,2 ,3 ]
Zhou, Sheng [1 ,2 ,3 ]
Wang, Ping [1 ,2 ,3 ]
Chen, Yueqiu [1 ,2 ,3 ]
Liu, Baorui [4 ,5 ]
Yu, Like [6 ]
Hou, Yayi [1 ,2 ,3 ]
机构
[1] Nanjing Univ, Immunol & Reprod Biol Lab, Sch Med, Nanjing, Jiangsu, Peoples R China
[2] Nanjing Univ, State Key Lab Pharmaceut Biotechnol, Nanjing, Jiangsu, Peoples R China
[3] Nanjing Univ, Jiangsu Key Lab Mol Med, Nanjing, Jiangsu, Peoples R China
[4] Nanjing Univ, Dept Oncol, Drum Tower Hosp, Sch Med, Nanjing, Jiangsu, Peoples R China
[5] Nanjing Univ, Clin Canc Inst, Nanjing, Jiangsu, Peoples R China
[6] Nanjing Chest Hosp, Dept Resp Med 1, Nanjing, Jiangsu, Peoples R China
来源
PLOS ONE | 2012年 / 7卷 / 08期
基金
中国国家自然科学基金;
关键词
PLEURAL EFFUSION; MESSENGER-RNA; GENE; CARCINOMA; PROGNOSIS; ONCOGENES; DIAGNOSIS; LEUKEMIA; BIOLOGY; RELAPSE;
D O I
10.1371/journal.pone.0043268
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objective: MicroRNAs (miRNAs) expression is altered in cancer cells, and miRNAs could serve as diagnostic and prognostic biomarker for cancer patients. This study was designed to analyze circulating miRNAs expression in the malignant pleural effusion (MPE) and their association with patient survival in non-small cell lung cancer (NSCLC). Methods: Pleural effusion from 184 patients with NSCLC and MPE were collected. MiRNA microarray and bioinformatics interpretation were used to evaluate miRNA expression profiles in 10 NSCLC patients with different survival prognosis. Associations were validated in 184 patients (randomly classified into training and validation set with equal number in each group) using quantitative RT-PCR. Risk scores were formulated based on the expression signature of miRNAs. Clinical data, such as patient survival, were collected for correlation analysis. Results: Thirty-three miRNAs were found to be altered more than two-fold by microarray in malignant effusions between longer-survival and shorter-survival groups, and levels of five miRNAs (miRNA-93, miRNA-100, miRNA-134, miRNA-151 and miRNA-345) were significantly associated with overall survival. High expression of miR-100 and low expression of miRNA-93, miRNA-134, miRNA-151 and miRNA-345 were associated with poor survival in both the training and validation cohort. Patients with high risk scores had overall poor survival compared to the patients with low risk scores. Risk score was an independent predictor of patient survival. Conclusions: Expression patterns of miRNAs are systematically altered in MPE of patient with NSCLC. The five miRNA signature from the effusion may serve as a predictor for the overall survival of patients with lung cancers.
引用
收藏
页数:7
相关论文
共 29 条
  • [1] Gene Ontology: tool for the unification of biology
    Ashburner, M
    Ball, CA
    Blake, JA
    Botstein, D
    Butler, H
    Cherry, JM
    Davis, AP
    Dolinski, K
    Dwight, SS
    Eppig, JT
    Harris, MA
    Hill, DP
    Issel-Tarver, L
    Kasarskis, A
    Lewis, S
    Matese, JC
    Richardson, JE
    Ringwald, M
    Rubin, GM
    Sherlock, G
    [J]. NATURE GENETICS, 2000, 25 (01) : 25 - 29
  • [2] Prognostic significance of pleural fluid data in patients with malignant effusion
    Bielsa, Silvia
    Salud, Antonieta
    Martinez, Montserrat
    Esquerda, Aureli
    Martin, Antonio
    Rodriguez-Panadero, Francisco
    Porcel, Jose M.
    [J]. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2008, 19 (05) : 334 - 339
  • [3] A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia
    Calin, GA
    Ferracin, M
    Cimmino, A
    Di Leva, G
    Shimizu, M
    Wojcik, SE
    Iorio, MV
    Visone, R
    Sever, NI
    Fabbri, M
    Iuliano, R
    Palumbo, T
    Pichiorri, F
    Roldo, C
    Garzon, R
    Sevignani, C
    Rassenti, L
    Alder, H
    Volinia, S
    Liu, CG
    Kipps, TJ
    Negrini, M
    Croce, CM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (17) : 1793 - 1801
  • [4] The properties of high-dimensional data spaces: implications for exploring gene and protein expression data
    Clarke, Robert
    Ressom, Habtom W.
    Wang, Antai
    Xuan, Jianhua
    Liu, Minetta C.
    Gehan, Edmund A.
    Wang, Yue
    [J]. NATURE REVIEWS CANCER, 2008, 8 (01) : 37 - 49
  • [5] Molecular origins of cancer: Oncogenes and cancer
    Croce, Carlo M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (05) : 502 - 511
  • [6] A systems biology approach for pathway level analysis
    Draghici, Sorin
    Khatri, Purvesh
    Tarca, Adi Laurentiu
    Amin, Kashyap
    Done, Arina
    Voichita, Calin
    Georgescu, Constantin
    Romero, Roberto
    [J]. GENOME RESEARCH, 2007, 17 (10) : 1537 - 1545
  • [7] miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer
    Gallardo, Elena
    Navarro, Alfons
    Vinolas, Nuria
    Marrades, Ramon M.
    Diaz, Tania
    Gel, Bernat
    Quera, Angels
    Bandres, Eva
    Garcia-Foncillas, Jesus
    Ramirez, Jose
    Monzo, Mariano
    [J]. CARCINOGENESIS, 2009, 30 (11) : 1903 - 1909
  • [8] Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis
    Guo, Linlang
    Liu, Yongguang
    Bai, Yifeng
    Sun, Yanqin
    Xiao, Faman
    Guo, Ying
    [J]. EUROPEAN JOURNAL OF CANCER, 2010, 46 (09) : 1692 - 1702
  • [9] Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: Correlations with patient survival and pleural effusion control
    Hsu, I-Lin
    Su, Wu-Chou
    Yan, Jing-Jou
    Chang, Jia-Ming
    Lai, Wu-Wei
    [J]. LUNG CANCER, 2009, 65 (03) : 371 - 376
  • [10] Serum MicroRNA Signatures Identified in a Genome-Wide Serum MicroRNA Expression Profiling Predict Survival of Non-Small-Cell Lung Cancer
    Hu, Zhibin
    Chen, Xi
    Zhao, Yang
    Tian, Tian
    Jin, Guangfu
    Shu, Yongqian
    Chen, Yijiang
    Xu, Lin
    Zen, Ke
    Zhang, Chenyu
    Shen, Hongbing
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (10) : 1721 - 1726